Brands
Discover
Events
Newsletter
More

Follow Us

twitterfacebookinstagramyoutube
Youtstory

Brands

Resources

Stories

General

In-Depth

Announcement

Reports

News

Funding

Startup Sectors

Women in tech

Sportstech

Agritech

E-Commerce

Education

Lifestyle

Entertainment

Art & Culture

Travel & Leisure

Curtain Raiser

Wine and Food

YSTV

ADVERTISEMENT
Advertise with us

[Funding alert] Genetic diagnostics player Lilac Insights raises Rs 50 Cr from Rajiv Dadlani, others

The 2011-incorporated company offers specialised diagnostics services for prenatal, newborn, and oncology or cancer disorders, and is planning to get into mental health counselling and genetic problems.

[Funding alert] Genetic diagnostics player Lilac Insights raises Rs 50 Cr from Rajiv Dadlani, others

Thursday February 18, 2021 , 2 min Read

Lilac Insights, a genetic diagnostic laboratory, has raised Rs 50 crore from various investors for expansion activities, a top official said on Thursday.

The round was led by banker Rajiv Dadlani, and also saw participation from Allana Group, Sajid Fazalbhoy, Sebi-registered fund Rockstud Capital, Kayenne Ventures (Singapore), Rahul Talwar, Associated Capsules Group, and Singapore-based Thakrals, the Navi Mumbai-based company said.

Its co-founder Subhamoy Dastidar told PTI that the company is valued at Rs 200 crore, and the new investors will be getting 25 percent stake. The promoters will be holding 60 percent stake, while a set of early investors will have 15 percent, he said.


The 2011-incorporated company offers specialised diagnostics services for prenatal, newborn, and oncology or cancer disorders, and is planning to get into counselling for mental health and genetic problems, he said.

Funding

The company, which had a revenue of Rs 40 crore last year and has been delivering profits since FY19 with a pre-tax profit margin of 70 percent, is also planning to expand to Navi Mumbai, Dastidar said.


He added that he is confident of taking the revenue up to Rs 300 crore in the next five years on the back of higher demand in the niche segment that it operates in.

Once the revenue touches Rs 300 crore, the company will be looking to go public through an initial public offering which can also give an exit opportunity to the existing investors, he said.

At present, a majority of its work is concentrated in the metro cities and other major cities of the country, he said, adding that it has 7,000 doctors and 1,700 hospitals in 250 cities or towns who send their samples for tests.


Its main lab is in Navi Mumbai and it also has a bigger lab in Bengaluru, he said, adding that there are satellite labs in Chandigarh, Pune, and Kolkata.


Edited by Kanishk Singh